IP Library Granted Patent US 9,631,231
Granted Patent B2
US 9,631,231 · App. 14/989,687 · Granted Apr 25, 2017

Compositions and methods for amplifying a nucleic acid sequence comprising a primer oligonucleotide with a 3′-terminal region comprising a 2′-modified nucleotide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,631,231
App. No.
14/989,687
Granted
Apr 25, 2017
Kind
B2
Abstract

The present invention features compositions and methods for amplifying a target oligonucleotide in a sample comprising one or more primer oligonucleotides comprising a 5′ nicking enzyme recognition site and a 3′-terminal region comprising a 2′-modified nucleotide. These methods are compatible with target oligonucleotides amplified using a nicking amplification reaction.

Claims (20)

1. A method of amplifying a polynucleotide, the method comprising:

(a) contacting a target nucleic acid molecule under substantially isothermal conditions with a polymerase, two or more primer oligonucleotides, each of which specifically binds to a complementary sequence on the target nucleic acid molecule, and a nicking enzyme, wherein each of the primer oligonucleotides comprises one or more 2′ modified nucleotides positioned at the 3′ end of the sequence complementary to the target nucleic acid molecule; and

(b) generating amplicons comprising at least a portion of said target nucleic acid molecule.

2. The method of claim 1 , further comprising detecting the amplicons.

3. The method of claim 2 , wherein the detection comprises binding the amplicons with a detectable probe.

4. The method of claim 1 , wherein one or more 2′ modified nucleotides positioned at the 5′ terminus of the sequence complementary to the target nucleic acid molecule are separated from the nick site by 1, 2, 3, 4, 5 or more unmodified nucleotides.

5. The method of claim 1 , wherein two or more 2′ modified nucleotides are contiguous.

6. The method of claim 1 , wherein 5 contiguous 2′-O-methyl modified nucleotides are positioned at the 3′ end of the sequence complementary to the target nucleic acid molecule.

7. The method of claim 1 , wherein 5 contiguous 2′-O-methyl modified nucleotides are positioned at the 5′ end of the sequence complementary to the target nucleic acid molecule.

8. A method of amplifying a polynucleotide, the method comprising:

(a) contacting a target nucleic acid molecule under substantially isothermal conditions with a polymerase, two primer oligonucleotides, each of which specifically binds to a complementary sequence on the target nucleic acid molecule, and a nicking enzyme, wherein each of the primer oligonucleotides comprises 5 contiguous 2′-O-methyl modified nucleotides positioned at the 3′ end of the sequence complementary to the target nucleic acid molecule; and

(b) generating amplicons comprising at least a portion of said target nucleic acid molecule.

9. A method of amplifying a polynucleotide derived from a pathogen, the method comprising:

(a) contacting a polynucleotide derived from a pathogen under substantially isothermal conditions with a polymerase, two or more primer oligonucleotides, each of which specifically binds to a complementary sequence on the target nucleic acid molecule, and a nicking enzyme, wherein each of the primer oligonucleotides comprises one or more 2′ modified nucleotides positioned at the 3′ end of the sequence complementary to the target nucleic acid molecule; and

(b) generating amplicons comprising at least a portion of said target nucleic acid molecule.

10. The method of claim 9 , further comprising detecting the amplicons with a detectable probe.

11. The method of claim 9 , wherein the pathogen is a virus, bacteria, yeast or fungus.

12. The method of claim 9 , wherein the pathogen is present in a biological sample.

13. The method of claim 12 , wherein the biological sample is selected from the group consisting of blood, serum, plasma, amniotic fluid, sputum, urine, semen, vaginal secretion, cerebrospinal fluid, lymph, tear fluid, feces, and gastric fluid.

14. The method of claim 9 , wherein the pathogen is present in an environmental sample.

Assignments (3)
SECURITY INTEREST Recorded Sep 5, 2025
From: ENSIGN-BICKFORD INDUSTRIES, INC.; APPLIED FOOD BIOTECHNOLOGY, INC.; EB ANALYTICS, INC.; ENSIGN-BICKFORD AEROSPACE & DEFENSE COMPANY; ENVIROLOGIX INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 072815/0001 →
SECURITY INTEREST Recorded Feb 4, 2021
From: ENSIGN-BICKFORD INDUSTRIES, INC.; APPLIED FOOD BIOTECHNOLOGY, INC.; ENSIGN-BICKFORD AEROSPACE & DEFENSE COMPANY; EB ANALYTICS, INC.; ENVIROLOGIX INC.; HONEYBEE ROBOTICS, LTD.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 055223/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2016
From: JUDICE, STEPHEN A.; SHAFFER, DANIEL
To: ENVIROLOGIX INC.
Reel/Frame 037489/0861 →